Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABM-1310 |
Synonyms | |
Therapy Description |
ABM-1310 inhibits BRAF V600, including BRAF V600E, potentially leading to inhibition of tumor growth (Cancer Res (2020) 80 (16_Supplement): 4038). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABM-1310 | ABM1310|ABM 1310 | BRAF Inhibitor 25 | ABM-1310 inhibits BRAF V600, including BRAF V600E, potentially leading to inhibition of tumor growth (Cancer Res (2020) 80 (16_Supplement): 4038). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600X | Advanced Solid Tumor | predicted - sensitive | ABM-1310 | Phase I | Actionable | In a Phase I trial, ABM-1310 treatment was tolerated and demonstrated preliminary efficacy in patients with advanced solid tumors harboring BRAF V600X, resulting in 2 partial responses (1 pleomorphic xanthroastrocytoma, 1 glioblastoma) and 8 stable diseases among 16 evaluable patients (J Clin Oncol 41, 2023 (suppl 16; abstr 3098); NCT04190628). | detail... |
BRAF V600X | brain cancer | predicted - sensitive | ABM-1310 | Phase I | Actionable | In a Phase I trial, ABM-1310 treatment was well tolerated and resulted in preliminary antitumor activity with 3 partial responses and 8 stable disease among 13 patients with brain tumors harboring BRAF V600 mutations, including a partial response in a patient with glioblastoma and 2 partial responses in patients with pleomorphic xanthoastrocytoma (Ann Oncol (2024) 35 (suppl_2): S411; NCT05892653). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04190628 | Phase I | ABM-1310 ABM-1310 + Cobimetinib | Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors | Terminated | USA | 0 |